Vasomedical Announces Strong Revenue Growth for the Three Months Ended March 31, 2012

Advanced Heart Disease Patient Regains Lost Energy, Attends 50-Year Class Reunion After Receiving EECP® Therapy at Heart House in Washington Township

Vasomedical Successfully Exhibited at the 61st Annual Scientific Sessions of the American College of Cardiology

Vasomedical Announces Record Operating Income of $5.2 Million and 169% Increase in Revenue for the Seven Months Ended December 31, 2011

Florida Cardiologist Tells Angina Patients, “Don’t Give Up Hope: Non-Invasive EECP® Therapy Can Relieve Chest Pain when Stents and Bypasses Do Not”

More >>

July 5, 2011

Vasomedical To Participate in the European Society of Cardiology (ESC) Congress in Paris, France on August 27-30, 2011

In support of our goal to improve the level of non-invasive healthcare products globally, Vasomedical will participate in the European Society of Cardiology (ESC) 2011 in Paris, France on August 27 – August 30, 2011, in booth #A300. The ESC Congress is currently the world’s premier conference on the science, management and prevention of cardiovascular disease.

Vasomedical will feature its full line of products at the ESC, including the company’s unique core technology, Enhanced External Counterpulsation (EECP®) therapy. The company will conduct live demonstrations of its therapy systems on its 4th generation model, the Lumenair™ EECP® therapy system. The Lumenair™ incorporates the clinically proven performance of EECP® technology in a sleek, all-in-one system and combines it with patient safety, patient comfort and ease of use. Vasomedical EECP® Therapy systems are the only non-invasive external counterpulsation therapy devices proven safe and effective in the treatment of angina and heart failure in clinical trials published in peer reviewed medical journals. There are currently over 150 published articles in medical literature on EECP® therapy.

“With its different mechanisms of action, EECP® therapy does not target the lesions that cause the symptoms in coronary artery disease (CAD), it targets the disease itself. Therefore, EECP® therapy does not replace the invasive revascularization techniques, but compliments them by offering a safe and effective treatment for CAD.” states Dr. Ozlem Soran, Associate Professor of Medicine and Epidemiology/Research at the UPMC Health System in Pittsburgh, Pennsylvania, who as an invited speaker will present as part of the scientific sessions at the ESC on August 29, 2011 on the subject of Enhanced External Counterpulsation Therapy as part of the symposium entitled The Challenge of Refractory Angina. The symposium chaired by Drs. Lanza (IT) and Manheimer (SE) is scheduled for 14:00 in Athens – Zone F.

In addition, Dr. Soran will present as lead author (Soran, Kennard and Kelsey), an accepted abstract on EECP® Therapy from the International EECP® Patient Registry entitled  A Comparison of Six Months Clinical Outcomes of Patients in the United States and Europe Undergoing Enhanced External Counterpulsation Therapy for Refractory Angina with Left Ventricular Dysfunction.

To further complement our non-invasive cardiology product offerings, Vasomedical will feature in its exhibit the complete line of BIOX™ ECG Holter and Ambulatory Blood Pressure Monitoring  (ABPM) products along with the EZ™ Patient Management Products. Of particular interest are the recently FDA cleared, extremely lightweight, LCD display BIOX™ Model 1303 ECG Recorder, Model 1304 12-Channel ECG Recorder and its unique combined ECG and ABPM Recorders, the Model 2301 Combined 3-Channel and Model 2302 12-Channel recorders respectively.

The Model 2301 and Model 2302 are the only U.S. FDA cleared, combined ECG and ABPM monitoring devices of their type in the world today. For those looking for an Ambulatory Blood Pressure  Monitor alone, the BIOX™ Model 1805 features our exclusive proprietary technology enabling the physician to record static pressure values as well as a pressure oscillation waveform and transfer the data to a PC.

For those patients who require additional monitoring at home, Vasomedical EZ™ Patient Management products offer compact and portable hand held EZ ECG™ and Finger Pulse Oximetry products. Whether the need is short term reading or long term monitoring with computer interface and recoding capability, the Vasomedical Patient Management products help the physician extend accurate, low cost monitoring care outside the hospital and office to the home.

For more product information on Vasomedical’s full line of EECP® systems, ECG Holter, ABPM and patient management products, visit our booth, #A300, at the ESC or on our website (www.vasomedical.com) under the Products tab on the main page.

Vasomedical, Inc. is engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of cardiovascular diseases and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. The Company also provides other noninvasive medical equipment including Holter monitors and ambulatory blood pressure monitors.

Vaso Diagnostics d/b/a VasoHealthcare, a wholly owned subsidiary of Vasomedical, Inc., is a professional sales representation organization offering vendors of medical devices an alternative third party sales channel. Through an agreement with GE Healthcare, it is currently engaged as an exclusive sales representative for certain GE Healthcare products.

Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.